Medical - Instruments & Supplies
Compare Stocks
2 / 10Stock Comparison
TFX vs ANGO
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
TFX vs ANGO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Instruments & Supplies |
| Market Cap | $5.83B | $469M |
| Revenue (TTM) | $2.81B | $307M |
| Net Income (TTM) | $-1.01B | $-28M |
| Gross Margin | 53.3% | 53.7% |
| Operating Margin | 5.6% | -9.4% |
| Forward P/E | 19.6x | — |
| Total Debt | $2.73B | $0.00 |
| Cash & Equiv. | $393M | $56M |
TFX vs ANGO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Teleflex Incorporat… (TFX) | 100 | 36.7 | -63.3% |
| AngioDynamics, Inc. (ANGO) | 100 | 109.7 | +9.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TFX vs ANGO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
TFX is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 0 yrs, beta 1.06, yield 1.0%
- Lower volatility, beta 1.06, Low D/E 87.2%, current ratio 2.54x
- Beta 1.06, yield 1.0%, current ratio 2.54x
ANGO carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth -3.8%, EPS growth 81.9%, 3Y rev CAGR -2.6%
- -9.2% 10Y total return vs TFX's -10.3%
- -3.8% revenue growth vs TFX's -34.6%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | -3.8% revenue growth vs TFX's -34.6% | |
| Quality / Margins | -9.0% margin vs TFX's -35.9% | |
| Stability / Safety | Beta 1.06 vs ANGO's 1.32 | |
| Dividends | 1.0% yield; the other pay no meaningful dividend | |
| Momentum (1Y) | +28.5% vs TFX's +9.0% | |
| Efficiency (ROA) | -10.3% ROA vs TFX's -13.9%, ROIC -22.9% vs 3.4% |
TFX vs ANGO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
TFX vs ANGO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
ANGO leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TFX is the larger business by revenue, generating $2.8B annually — 9.1x ANGO's $307M. ANGO is the more profitable business, keeping -9.0% of every revenue dollar as net income compared to TFX's -35.9%. On growth, ANGO holds the edge at +9.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $2.8B | $307M |
| EBITDAEarnings before interest/tax | $280M | -$5M |
| Net IncomeAfter-tax profit | -$1.0B | -$28M |
| Free Cash FlowCash after capex | $249M | -$9M |
| Gross MarginGross profit ÷ Revenue | +53.3% | +53.7% |
| Operating MarginEBIT ÷ Revenue | +5.6% | -9.4% |
| Net MarginNet income ÷ Revenue | -35.9% | -9.0% |
| FCF MarginFCF ÷ Revenue | +8.9% | -3.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -21.8% | +9.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -108.7% | +42.3% |
Valuation Metrics
ANGO leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $5.8B | $469M |
| Enterprise ValueMkt cap + debt − cash | $8.2B | $413M |
| Trailing P/EPrice ÷ TTM EPS | -6.50x | -13.58x |
| Forward P/EPrice ÷ next-FY EPS est. | 19.59x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 18.82x | — |
| Price / SalesMarket cap ÷ Revenue | 2.93x | 1.60x |
| Price / BookPrice ÷ Book value/share | 1.88x | 2.52x |
| Price / FCFMarket cap ÷ FCF | 23.75x | — |
Profitability & Efficiency
ANGO leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
ANGO delivers a -15.7% return on equity — every $100 of shareholder capital generates $-16 in annual profit, vs $-28 for TFX.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -28.3% | -15.7% |
| ROA (TTM)Return on assets | -13.9% | -10.3% |
| ROICReturn on invested capital | +3.4% | -22.9% |
| ROCEReturn on capital employed | +4.0% | -18.6% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 |
| Debt / EquityFinancial leverage | 0.87x | — |
| Net DebtTotal debt minus cash | $2.3B | -$56M |
| Cash & Equiv.Liquid assets | $393M | $56M |
| Total DebtShort + long-term debt | $2.7B | $0 |
| Interest CoverageEBIT ÷ Interest expense | -2.02x | -258.19x |
Total Returns (Dividends Reinvested)
ANGO leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ANGO five years ago would be worth $4,674 today (with dividends reinvested), compared to $3,357 for TFX. Over the past 12 months, ANGO leads with a +28.5% total return vs TFX's +9.0%. The 3-year compound annual growth rate (CAGR) favors ANGO at 7.9% vs TFX's -19.4% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +7.9% | -11.1% |
| 1-Year ReturnPast 12 months | +9.0% | +28.5% |
| 3-Year ReturnCumulative with dividends | -47.6% | +25.8% |
| 5-Year ReturnCumulative with dividends | -66.4% | -53.3% |
| 10-Year ReturnCumulative with dividends | -10.3% | -9.2% |
| CAGR (3Y)Annualised 3-year return | -19.4% | +7.9% |
Risk & Volatility
TFX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
TFX is the less volatile stock with a 1.06 beta — it tends to amplify market swings less than ANGO's 1.32 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TFX currently trades 94.3% from its 52-week high vs ANGO's 80.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.03x | 1.32x |
| 52-Week HighHighest price in past year | $139.63 | $13.99 |
| 52-Week LowLowest price in past year | $100.18 | $8.36 |
| % of 52W HighCurrent price vs 52-week peak | +94.3% | +80.6% |
| RSI (14)Momentum oscillator 0–100 | 48.5 | 54.0 |
| Avg Volume (50D)Average daily shares traded | 884K | 395K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates TFX as "Buy" and ANGO as "Hold". Consensus price targets imply 46.4% upside for ANGO (target: $17) vs 0.4% for TFX (target: $132). TFX is the only dividend payer here at 1.02% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | $132.20 | $16.50 |
| # AnalystsCovering analysts | 29 | 11 |
| Dividend YieldAnnual dividend ÷ price | +1.0% | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | $1.35 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +5.1% | +0.4% |
ANGO leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). TFX leads in 1 (Risk & Volatility).
TFX vs ANGO: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is TFX or ANGO a better buy right now?
For growth investors, AngioDynamics, Inc.
(ANGO) is the stronger pick with -3. 8% revenue growth year-over-year, versus -34. 6% for Teleflex Incorporated (TFX). Analysts rate Teleflex Incorporated (TFX) a "Buy" — based on 29 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TFX or ANGO?
Over the past 5 years, AngioDynamics, Inc.
(ANGO) delivered a total return of -53. 3%, compared to -66. 4% for Teleflex Incorporated (TFX). Over 10 years, the gap is even starker: ANGO returned -9. 2% versus TFX's -9. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TFX or ANGO?
By beta (market sensitivity over 5 years), Teleflex Incorporated (TFX) is the lower-risk stock at 1.
03β versus AngioDynamics, Inc. 's 1. 32β — meaning ANGO is approximately 28% more volatile than TFX relative to the S&P 500.
04Which is growing faster — TFX or ANGO?
By revenue growth (latest reported year), AngioDynamics, Inc.
(ANGO) is pulling ahead at -3. 8% versus -34. 6% for Teleflex Incorporated (TFX). On earnings-per-share growth, the picture is similar: AngioDynamics, Inc. grew EPS 81. 9% year-over-year, compared to -1468. 2% for Teleflex Incorporated. Over a 3-year CAGR, ANGO leads at -2. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — TFX or ANGO?
AngioDynamics, Inc.
(ANGO) is the more profitable company, earning -11. 6% net margin versus -45. 4% for Teleflex Incorporated — meaning it keeps -11. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TFX leads at 12. 8% versus -13. 7% for ANGO. At the gross margin level — before operating expenses — TFX leads at 56. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is TFX or ANGO more undervalued right now?
Analyst consensus price targets imply the most upside for ANGO: 46.
4% to $16. 50.
07Which pays a better dividend — TFX or ANGO?
In this comparison, TFX (1.
0% yield) pays a dividend. ANGO does not pay a meaningful dividend and should not be held primarily for income.
08Is TFX or ANGO better for a retirement portfolio?
For long-horizon retirement investors, Teleflex Incorporated (TFX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
03), 1. 0% yield). Both have compounded well over 10 years (TFX: -9. 4%, ANGO: -9. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between TFX and ANGO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
TFX pays a dividend while ANGO does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.